Evidence map›Paper›PMID 40097500›Full record

ArticleScientific reports2025

A Nanostring gene expression approach identifies aggressive clinical behavior related genes in dedifferentiated liposarcoma.

Francesca Zalfa, Paolo Manca, Simone Carotti, Silvia Vallese, Daniela Righi, Chiara Taffon, Lorenzo Nibid, Marta Sbaraglia, Carla Rabitti, Francesco Pantano and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Francesca ZalfaOperative Research Unit of Predictive Molecular Diagnostic, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy. f.zalfa@unicampus.it.
Paolo MancaMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Simone CarottiOperative Research Unit of Predictive Molecular Diagnostic, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Silvia VallesePathology Unit, Bambino Gesù Children's Hospital, IRCCS, 00165, Rome, Italy.
Daniela RighiOperative Research Unit of Predictive Molecular Diagnostic, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Chiara TaffonOperative Research Unit of Anatomical Pathology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Lorenzo NibidOperative Research Unit of Anatomical Pathology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Marta SbaragliaDepartment of Medicine DIMED, University of Padua, Padua, Italy.
Carla RabittiOperative Research Unit of Anatomical Pathology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Francesco PantanoOperative Research Unit of Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Giuseppe ToniniOperative Research Unit of Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Angelo Paolo Dei TosDepartment of Medicine DIMED, University of Padua, Padua, Italy.
Bruno Vincenzi *Operative Research Unit of Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Giuseppe Perrone *Operative Research Unit of Anatomical Pathology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.

Funding

Università Campus Bio-Medico di Roma GR7017
6 · The paper itself

Abstract

Dedifferentiated liposarcoma (DDLPS) is one of the most common subtypes of soft tissue sarcoma with a highly variable clinical behavior. Despite advanced molecular approaches are exploring the genetic panorama of DDLPS progression, to date the driver genes of the aggressive clinical behavior in DDLPS have not been identified yet. Here, we used a Nanostring nCounter approach to study the gene expression profile of 60 selected genes involved in DDLPS progression, in a cohort of DDLPS with aggressive clinical behavior, in comparison to a cohort of DDLPS with indolent clinical behavior. We identified five genes whose expression is significantly and consistently altered in aggressive compared to indolent DDLPS. Moreover, by a clinical outcome analyses we found MAP3K12 gene expression linked with both a higher risk of metastases and death. We envisage that the identified genes could represent the first genes of a genetic signature able to predict the clinical evolution of a DDLPS.

Indexed as

Gene Expression ProfilingGene Expression Regulation, NeoplasticLiposarcomaAdultAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisTranscriptomeBiomarkers, TumorAggressive clinical behaviorDDLPSGene expressionNanoString

Identifiers

PMID40097500
PMCPMC11914264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.